The MCCC employs both internal and external review mechanisms to inform the strategic decisions made by the Center and to provide feedback necessary for ongoing evaluation of the effectiveness of those decisions. The MCCC's efforts in this regard are broad and encompassing, employing a variety of strategies. Processes are in place for overall strategic planning, review of the established and developing programs, and review of the established and developing shared facilities. They are guided by a clear vision for the Center developed by the Center Director and Senior Leadership and facilitated by Cancer Center Administration. The vision is consistent with the goals of the NCI Centers Program and the mission of the Mayo Clinic, and built upon a careful assessment of the current and future scientific opportunities in cancer research and how the unique capabilities of Mayo Clinic can be leveraged to define areas of particular strength. This overall vision is used to help evaluate recommendations brought forward by leaders of programs and shared facilities - and even individual Center members. These efforts thus inform site and center-wide priorities for portfolio and programmatic stabilization and growth, integration, investment in infrastructure - notably shared resources, recruitment, health disparities and facilities, and use of discretionary resources including CCSG Developmental Funds. The MCCC utilizes expert outside scientists and administrators to provide insight and evaluative expertise in the ongoing review of the Cancer Center. The mainstay of the MCCC's planning and evaluation is the input provided by the External Advisory Committee (EAC). This group, reconstituted and expanded following Dr. Diasio's recruitment in the fall of 2006, has been indispensable in guiding the MCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-35
Application #
7944871
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-17
Project End
2014-02-28
Budget Start
2009-04-17
Budget End
2010-02-28
Support Year
35
Fiscal Year
2009
Total Cost
$35,346
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications